| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5590747 | Multiple Sclerosis and Related Disorders | 2017 | 18 Pages |
Abstract
A reduction in PK11195 uptake was observed in both enhancing and chronic lesions after the start of natalizumab. PK11195 PET can be used as tool to assess the longitudinal change in MS lesions.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Ulrike W. Kaunzner, Yeona Kang, Elizabeth Monohan, Paresh J. Kothari, Nancy Nealon, Jai Perumal, Timothy Vartanian, Amy Kuceyeski, Shankar Vallabhajosula, P. David Mozley, Claire S. Riley, Stephen M. Newman, Susan A. Gauthier,